CAP, n (%) | UTI, n (%) | AOM, n (%) | RHI, n (%) | PHA, n (%) | |
Recommendations considering resistance patterns | |||||
Antibiotic used as an alternative because of high resistance rate | 14 (19.2) | 9 (14.3) | 5 (11.9) | 3 (7.7) | 1 (2.9) |
Antibiotic not indicated because of high resistance rate | 2 (2.7) | 6 (9.5) | 1 (2.4) | 3 (7.7) | 5 (14.7) |
Resistance risk | 12 (16.4) | 7 (11.1) | 4 (9.5) | 3 (7.7) | _ |
Resistance threshold | _ | 9 (14.3) | _ | 2 (5.1) | 2 (5.9) |
Resistance AB | _ | 5 (7.9%) | _ | _ | _ |
Resistance dosage | 8 (11.0) | _ | 7 (16.7) | 8 (20.5) | _ |
Atypical pathogens | 19 (26.0) | _ | _ | _ | 1 (2.9) |
MRSA risk | 7 (9.6) | _ | _ | _ | _ |
MDR risk | 1 (1.4) | 5 (7.9) | 1 (2.4) | _ | _ |
PRSP risk | 6 (8.2) | _ | 6 (14.3) | 5 (12.8) | _ |
Pseudomonas risk | 14 (19.2) | _ | _ | _ | _ |
Beta-lactamase risk | 8 (11.0) | _ | 11 (26.2) | 7 (17.9) | _ |
Discrete resistance patterns mentioned in recommendations | |||||
Total | 10 | 6 | 7 | 7 | 4 |
Median n (%) | 3 (30.0) | 2 (33.3) | 2 (28.6) | 3.5 (50.0) | 1 (25.0) |
IQR n (%) | 2–3 (20–30) | 2–5 (33.3–83.3) | 1.3–3 (17.9–42.9) | 1.7–4 (21.4–57.1) | 1–1 (25–25) |
AOM, acute otitis media; Atypical pathogens, risk of atypical pathogens; CAP, community acquired pneumonia; MDR risk, risk of multidrug resistant strains; MRSA risk, risk of meticillin-resistant Staphylococcus aureus; PHA, pharyngitis; PRSP risk, risk of penicillin resistant Streptococcus pneumonia; Pseudomonas risk, risk of Pseudomonas aeruginosa; Resistance AB, antibiotic used if first-line AB is resistant; Resistance dosage, antibiotic used at high dosage if there is a risk of resistant strains; Resistance risk, antibiotic used only if there is a risk of increasing resistance (eg, recent use of critical AB during past months); Resistance threshold, antibiotic used only under a certain threshold of resistance; RHI, rhinosinusitis; UTI, urinary tract infection; beta-lactamase risk, risk of strains producing beta-lactamase.